版本:
中国

BRIEF-Asterias Biotherapeutics announces data monitoring committee

April 25 Asterias Biotherapeutics Inc

* Asterias Biotherapeutics announces data monitoring committee unanimously recommends continuation of scistar phase 1/2A clinical trial of AST-OPC1 for cervical spinal cord injury

* Expects to report additional efficacy and safety data for Cohort 2, and for currently-enrolling cohorts 3 and 4, later this year Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐